Investor Portal

Previous Sectors

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration Two-year results from CEDAR and SEQUOIA demonstrate that vision gains observed after one year with every 8-week and every 12-week dosing were maintained in the second year Abicipar [...]

2019-10-22T11:02:49+01:00October 14th, 2019|All News, Company News, Previous Sectors|

Allergan & Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation

Allergan & Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation The acceptance and authorisation are for Abicipar pegol in patients with neovascular (wet) age-related macular degeneration Filing includes data from two Phase 3 trials which evaluated the safety and efficacy [...]

2019-10-10T10:53:56+01:00September 9th, 2019|All News, Company News, Previous Sectors|

Molecular Partners’ strategic partner Allergan announces that EMA has validated the marketing authorisation application for abicipar

Molecular Partners’ strategic partner Allergan announces that EMA has validated the marketing authorisation application for abicipar CAESAREA, Israel, Aug. 15, 2019 — V-Wave Ltd., a privately held medical device company developing novel implantable interatrial shunt devices, today announced that the U.S. Food and Drug Administration (FDA) has just granted [...]

2019-10-10T09:43:07+01:00August 7th, 2019|All News, Company News, Previous Sectors|

Molecular Partners and Amgen announce strategic collaboration in immuno-oncology

Molecular Partners and Amgen announce strategic collaboration in immuno-oncology Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB MultiSpecific DARPin® Molecule, in Combination with Amgen’s Oncology Assets, Including BiTE® Molecules Molecular Partners Retains Rights to Develop MP0310 in Combination With its Pipeline Products ZURICH-SCHLIEREN, SWITZERLAND and THOUSAND [...]

2019-10-10T14:13:43+01:00December 19th, 2018|All News, Company News, Previous Sectors|

Molecular Partners provides additional details on clinical studies of proprietary lead oncology asset MP0250

Molecular Partners provides additional details on clinical studies of proprietary lead oncology asset MP0250 Zurich-Schlieren, May 30, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the first patient was dosed in the phase [...]

2019-10-09T15:45:28+01:00May 30th, 2017|All News, Company News, Previous Sectors|

Patrick Amstutz Appointed as Molecular Partners’ Chief Executive Officer

Patrick Amstutz Appointed as Molecular Partners’ Chief Executive Officer Zurich-Schlieren, May 12, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the Board of Directors unanimously decided to appoint Patrick Amstutz, Ph.D., cofounder of [...]

2019-10-09T14:52:44+01:00May 12th, 2017|All News, Company News, Previous Sectors|

Molecular Partners reports changes in ownership

Molecular Partners reports changes in ownership Long-term venture capital investors holding reduced to 28% of share capital Private investors acquired shares from venture capitalist investors in secondary block trades Zurich-Schlieren, April 6, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs [...]

2019-10-09T14:43:11+01:00April 6th, 2017|All News, Company News, Previous Sectors|

First patient enrolled in phase III study of abicipar – Molecular Partners receives USD 15 million milestone payment

First patient enrolled in phase III study of abicipar – Molecular Partners receives USD 15 million milestone payment Zurich‐Schlieren, July 07, 2015. Molecular Partners AG (ticker: MOLN) today announced that its partner Allergan has initiated phase III clinical trials with abicipar pegol (abicipar) for the treatment of wet [...]

2019-10-09T14:58:47+01:00July 7th, 2015|All News, Company News, Previous Sectors|

HGST Announces Definitive Agreement To Acquire Amplidata

HGST Announces Definitive Agreement To Acquire Amplidata Acquisition Supports Strategy to Expand into Higher Value Storage Platforms and Systems IRVINE and MILPITAS, Calif., March 3, 2015 /PRNewswire/ — Western Digital® Corporation (NASDAQ: WDC) announced today that HGST has entered into a definitive agreement to acquire Amplidata, a privately-held [...]

2019-10-09T15:48:32+01:00March 3rd, 2015|All News, Company News, Previous Sectors|